Dutch imaging giant Philips today announced it is collaborating with RXi Pharmaceuticals, a discovery-stage biopharmaceutical company, on the research and development of a new class of therapeutics based on RNA interference (RNAi). Diseases are associated with specific processes at ...
Please Login to read the full article.
